Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on February 14, 2018. The report discloses modifications to the compensatory arrangements of the Company's executive officers, effective January 1, 2018, following an annual review by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved the following changes to executive compensation:
- Jack A. Khattar (CEO): Base salary increased from $614,000 to $724,000. Received a 2017 bonus of $498,000 and options for 250,000 shares. 2018 bonus target increased to 75% of base salary (from 70%).
- Gregory S. Patrick (CFO): Base salary increased from $351,000 to $362,000. Received a 2017 bonus of $143,000 and options for 30,000 shares. 2018 bonus target remains 40% of base salary.
- Stefan K.F. Schwabe (CMO): Base salary increased from $378,000 to $390,000. Received a 2017 bonus of $159,000 and options for 30,000 shares. 2018 bonus target remains 40% of base salary.
- Padmanabh P. Bhatt (CSO): Base salary increased from $358,000 to $369,000. Received a 2017 bonus of $137,000 and options for 30,000 shares. 2018 bonus target remains 35% of base salary.
- Victor L. Vaughn (SVP Sales & Marketing): Base salary increased from $331,000 to $340,000. Received a 2017 bonus of $145,000 and options for 33,000 shares. 2018 bonus target remains 40% of base salary.
All stock option grants have an exercise price of $39.40 per share and vest annually in equal increments over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The compensation increases were recommended by Radford, the Company's independent compensation consultant, and are stated to be consistent with the industry peer group.
Investor Verification Points
- Verify the total number of shares granted to executives (373,000 total) against the Company's authorized share count and dilution impact.
- Confirm the exercise price of $39.40 per share relative to the stock's market performance post-February 14, 2018.
- Review the Company's annual proxy statement for the full details of the Compensation Committee's peer group analysis and performance metrics.
- Check subsequent filings for any changes to the vesting schedule or additional compensation adjustments.